SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...

Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

Additionally, GSK reported promising phase III results from the ANCHOR-1 and ANCHOR-2 trials, further supporting depemokimab’s efficacy in CRSwNP, with sustained improvements observed over 52 weeks.

Objectives: We reviewed asthma coexistence and the selection of biologic therapies in CRSwNP Management. Methods: The literature review utilized Google and Google Scholar, in addition to PubMed, EBSCO ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous ...

Moreover, up to 80% of individuals with chronic rhinosinusitis with nasal polyps (CRSwNP) also exhibit Type 2 inflammation. Currently, several monoclonal antibodies targeting IL-5 or its receptor are ...

Now, late-stage data in the respiratory condition chronic rhinosinusitis with nasal polyps, or CRSwNP, showed that the drug reduces the need for surgery by a startling 98% and the use of ...